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Abstract: Bladder cancers are a mixture of heterogeneous cell populations, and numerous factors are likely to be involved 
in dictating their recurrence, progression and the patient’s survival. For any candidate prognostic marker to have consider-
able clinical relevance, it must add some predictive capacity beyond that offered by conventional clinical and pathologic 
parameters. Here, the current situation in bladder cancer research with respect to identiﬁ  cation of suitable prognostic mark-
ers is reviewed. A number of individual molecular markers that might predict bladder cancer recurrence and progression 
have been identiﬁ  ed but many are not sufﬁ  ciently sensitive or speciﬁ  c for the whole spectrum of bladder cancer diseases 
seen in routine clinical practice. These limitations have led to interest in other molecular parameters that could enable more 
accurate prognosis for bladder cancer patients. Of particular interest is the epigenetic silencing of tumor suppressor genes. 
Since the methylation of these genes can correlate with a poor prognosis, the methylation proﬁ  le may represent a new bio-
marker that indicates the risk of transitional cell carcinoma development. In addition, bladder cancer research is likely to 
be revolutionized by high-throughput molecular technologies, which allow rapid and global gene expression analysis of 
thousands of tumor samples. Initial studies employing these technologies have considerably expanded our ability to clas-
sify bladder cancers with respect to their survivability. Future microarray analyses are likely to reveal particular gene ex-
pression signatures that predict the likelihood of bladder cancer progression and recurrence, as well as patient’s survival 
and responsiveness to different anti-cancer therapies, with great speciﬁ  city and sensitivity.
Keywords: Bladder cancer, Biomarker, Prognosis.
Introduction
Currently, patients with bladder cancer are monitored for cancer recurrence or progression by periodic 
cystoscopy, the frequency of which varies depending on the risk factors associated with the disease. 
The assumption is that frequent cystoscopies facilitate the treatment of recurrences at an early stage, 
thereby potentially slowing the progression of the disease to muscle invasive disease. It has also been 
shown that assessment of the urine for the presence of particular cells or various bladder tumor markers 
can help prediction of tumor recurrence, progression, and metastasis. Therefore, inspection of urine 
samples can forecast the patient’s survival and response to various treatments. Urine cytology is a highly 
speciﬁ  c, noninvasive adjunct to cystoscopy that is quite sensitive in detecting high grade bladder cancers. 
However, it has poor sensitivity in detecting low grade disease, and its accuracy is dependent on the 
pathologist’s experience.
To date, numerous potential markers from patient’s serum, bladder washes, urinary specimens, and 
cancer tissues have been identiﬁ  ed by a variety of molecular biology and genetic studies. Molecular 
markers such as Ki-67 and p53 do appear to have some promising correlations with bladder cancer 
development, but their predictive value remains to be conclusively veriﬁ  ed. This review focuses on 
recent advances in bladder cancer research with respect to the identiﬁ  cation of suitable molecular prog-
nostic markers.
Chromosomal Markers
Cytogenetic studies have identiﬁ  ed many changes in the structure and copy number of chromosomes in 
transitional cell carcinomas of the urinary bladder. For example, loss of heterozygosity (LOH) studies 
have shown that the loss of 17p, 3p, 13q, 18q, or 10q is found more frequently in high grade, high stage Biomarker Insights 2007: 2 96
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bladder cancer (Knowles, 2001). Moreover, loss of 
9q was observed in low as well as high grade bladder 
cancer, which suggests that the loss of 9q may be a 
primary event in the genesis of bladder cancer (Tsai 
et al. 1990). In superﬁ  cial bladder cancers, early 
changes include deletions of 11p and 8p, and gains 
of 8q and 1q (Fadl-Elmula et al. 2001). Such super-
ﬁ  cial noninvasive papillary lesions do not exhibit 
LOH of 17p, unlike invasive cancers, 60% of which 
exhibited LOH of 17p (Olumi et al. 1990; Presti 
et al. 1991). Thus, LOH of 17p may participate in 
the progression of bladder cancer. However, the 
prognostic value of these changes in chromosome 
copy numbers requires further large prospective 
studies of patients with bladder cancer. Indeed, it 
has been suggested that although copy number 
alterations have been associated with progression-
free survival, they are not independent prognostic 
factors for disease progression (Pycha et al. 1999).
Many tumors also bear DNA replication errors 
(RERs), where bases in simple mononucleotide 
or dinucleotide repeat sequences (microsatellites) 
have been added or deleted, when compared to 
the matching DNA of normal tissue specimens 
(Thibodeau et al. 1993). These RERs, which result 
in so-called microsatellite instability (MSI), arise 
from dysfunction of the DNA mismatch repair 
genes (hMSH2, hMLH1, hMSH6, PMS1, and 
PMS2). These alterations sometimes occur in 
microsatellites residing in the coding sequence of 
important growth regulatory genes and thereby 
contribute to the development of cancer (Pelto-
maki and de la Chapelle, 1997). One study has 
shown that microsatellite alterations in bladder 
cancer are associated with invasive cancer (Sardi 
et al. 1999), but this ﬁ  nding requires further veri-
ﬁ  cation. Meanwhile, many other studies have 
examined whether the shifted DNA bands in 
exfoliated urine or bladder wash cells that indicate 
MSI may be useful in the early diagnosis and 
follow up of bladder cancer (Uchida et al. 1996; 
Larsson et al. 2001; Seripa et al. 2001). However, 
it should be noted that microsatellite alterations 
in urine are indicators not only of malignancy but 
also of inﬂ  ammatory conditions (Christensen 
et al. 2000). Thus, the search for MSI can only 
complement current diagnostic methods.
Genetic Markers
Many of the genetic markers that are associated 
with bladder cancer have been subjected to exten-
sive studies examining their biological roles in 
bladder cancer development and progression. Here, 
we focus on the more promising prognostic 
markers. These include proto-oncogenes/onco-
genes, tumor suppressor genes, cell cycle regula-
tors, and cell adhesion molecules (Table 1). 
Proto-oncogenes/oncogenes
Several investigators have shown a positive corre-
lation between overexpression of epidermal growth 
factor receptor (EGFR) [as detected by immuno-
histochemistry (IHC)] and high grade, high stage 
bladder cancer, which suggests that EGFR expres-
sion is an independent prognostic factor that indi-
cates advanced bladder cancer (Neal et al. 1985; 
Messing, 1990; Nguyen et al. 1994; Lipponen and 
Eskelinen, 1994). The product of the HER-2/neu 
(c-erb-B2) oncogene was also found to be 
frequently overexpressed in urinary bladder cancer 
(Lipponen et al. 1991) and to correlate with 
increased tumor grade, lowered cancer-speciﬁ  c 
survival, and a higher incidence of metastatic 
disease (Sato et al. 1992). However, different 
studies examining the prognostic signiﬁ  cance of 
HER-2/neu protein expression levels in bladder 
cancer came to varying conclusions:some suggested 
a better or worse prognosis, while others failed to 
detect any prognostic relevance (Gandour-Edwards 
et al. 2002). 
Genetic studies have also shown that FGFR3 
point mutations occur frequently in bladder cancers 
(Cappellen et al. 1999; van Rhijn et al. 2001). Since 
these FGFR3 mutations occur particularly often in 
low grade and low stage bladder tumors, they could 
have prognostic value (van Rhijn et al. 2003). 
Another proto-oncogene that is frequently overex-
pressed in high grade bladder cancers is c-myc. 
However, these changes in c-myc expression do 
not appear to correlate with recurrence, progres-
sion, or survival (Kotake et al. 1990; Lipponen, 
1995; Schmitz-Drager et al. 1997). Therefore, 
c-myc overexpression in bladder cancer may be of 
little prognostic signiﬁ  cance.
Tumor suppressor genes
p53 plays a key role in regulating cell cycle 
progression and apoptosis under genotoxic condi-
tions and p53 gene mutations are the most 
commonly occurring genetic defect found in 
human cancers (Hollstein et al. 1991). In bladder 
cancer, p53 gene mutations are generally believed 
to indicate invasive bladder cancer and disease 
progression and to be useful as chemotherapy Biomarker Insights 2007: 2 97
Biomarkers of bladder cancer
T
a
b
l
e
 
1
.
 
P
o
t
e
n
t
i
a
l
 
g
e
n
e
t
i
c
 
m
a
r
k
e
r
s
 
i
n
 
b
l
a
d
d
e
r
 
c
a
n
c
e
r
.
M
a
r
k
e
r
s
 
L
o
c
u
s
 
M
e
t
h
o
d
s
 
P
o
t
e
n
t
i
a
l
 
p
r
o
g
n
o
s
t
i
c
 
v
a
l
u
e
 
R
e
f
e
r
e
n
c
e
P
r
o
t
o
-
o
n
c
o
g
e
n
e
s
/
O
n
c
o
g
e
n
e
s
 
 
 
 
E
G
F
R
 
7
p
1
2
 
I
H
C
 
H
i
g
h
 
g
r
a
d
e
/
h
i
g
h
 
s
t
a
g
e
 
(
N
e
a
l
 
e
t
 
a
l
.
 
1
9
8
5
;
 
M
e
s
s
i
n
g
1
9
9
0
;
 
 
 
 
 
 
 
 
N
g
u
y
e
n
 
e
t
 
a
l
.
 
1
9
9
4
;
 
L
i
p
p
o
n
e
n
 
a
n
d
 
 
 
 
 
 
 
E
s
k
e
l
i
n
e
n
,
 
1
9
9
4
)
H
E
R
-
2
/
n
e
u
 
(
c
-
e
r
b
-
B
2
)
 
1
7
q
2
1
.
1
 
I
H
C
 
H
i
g
h
 
g
r
a
d
e
/
h
i
g
h
 
s
t
a
g
e
/
p
o
o
r
 
(
L
i
p
p
o
n
e
n
 
e
t
 
a
l
.
 
1
9
9
1
;
 
(
S
a
t
o
 
e
t
 
a
l
.
 
1
9
9
2
)
)
 
 
 
 
s
u
r
v
i
v
a
l
/
m
e
t
a
s
t
a
s
i
s
F
G
F
R
3
 
4
p
1
6
.
3
 
P
C
R
 
L
o
w
 
g
r
a
d
e
/
l
o
w
 
s
t
a
g
e
/
 
p
r
o
g
n
o
s
i
s
 
 
(
R
h
i
j
n
 
e
t
 
a
l
.
 
2
0
0
1
;
 
v
a
n
 
R
h
i
j
n
 
e
t
 
a
l
.
 
2
0
0
3
)
 
 
 
(
r
e
c
u
r
r
e
n
c
e
,
 
p
r
o
g
r
e
s
s
i
o
n
,
 
s
u
r
v
i
v
a
l
)
c
-
m
y
c
 
8
q
2
4
 
I
H
C
 
N
o
 
a
s
s
o
c
i
a
t
i
o
n
 
w
i
t
h
 
r
e
c
u
r
r
e
n
c
e
,
 
(
K
o
t
a
k
e
 
e
t
 
a
l
.
 
1
9
9
0
;
 
L
i
p
p
o
n
e
n
,
 
1
9
9
5
;
 
 
 
 
 
 
p
r
o
g
r
e
s
s
i
o
n
,
 
o
r
 
s
u
r
v
i
v
a
l
 
S
c
h
m
i
t
z
-
D
r
a
g
e
r
 
e
t
 
a
l
.
 
1
9
9
7
)
 
T
u
m
o
r
 
S
u
p
p
r
e
s
s
o
r
 
G
e
n
e
s
 
 
 
 
p
5
3
 
1
7
p
1
3
.
1
 
I
H
C
 
H
i
g
h
 
s
t
a
g
e
/
 
p
r
o
g
n
o
s
i
s
 
(
r
e
c
u
r
r
e
n
c
e
,
 
(
S
c
h
m
i
t
z
-
D
r
a
g
e
r
 
e
t
 
a
l
.
 
2
0
0
0
;
 
 
 
p
r
o
g
r
e
s
s
i
o
n
,
 
s
u
r
v
i
v
a
l
)
/
R
e
s
i
s
t
a
n
c
e
 
t
o
 
 
S
a
r
k
i
s
 
e
t
 
a
l
.
 
1
9
9
5
;
 
S
e
n
g
e
l
o
v
 
e
t
 
a
l
.
 
1
9
9
7
)
 
 
 
c
h
e
m
o
t
h
e
r
a
p
y
 
R
b
 
1
3
q
1
4
.
2
 
I
H
C
 
H
i
g
h
 
s
t
a
g
e
/
 
p
r
o
g
n
o
s
i
s
 
(
r
e
c
u
r
r
e
n
c
e
,
 
(
C
o
r
d
o
n
-
C
a
r
d
o
 
e
t
 
a
l
.
 
1
9
9
2
;
 
L
o
g
o
t
h
e
t
i
s
 
 
 
p
r
o
g
r
e
s
s
i
o
n
,
 
s
u
r
v
i
v
a
l
)
 
 
e
t
 
a
l
.
 
1
9
9
2
;
 
C
o
t
e
 
e
t
 
a
l
.
 
1
9
9
8
)
C
e
l
l
 
C
y
c
l
e
 
R
e
g
u
l
a
t
o
r
s
 
 
 
 
p
2
1
 
6
p
2
1
.
2
 
I
H
C
 
H
i
g
h
 
s
t
a
g
e
/
 
p
r
o
g
n
o
s
i
s
 
(
r
e
c
u
r
r
e
n
c
e
,
 
s
u
r
v
i
v
a
l
)
 
(
S
t
e
i
n
 
e
t
 
a
l
.
 
1
9
9
8
)
p
2
7
 
1
2
p
1
3
.
1
 
I
H
C
 
H
i
g
h
 
g
r
a
d
e
/
s
u
r
v
i
v
a
l
 
(
K
o
r
k
o
l
o
p
o
u
l
o
u
 
e
t
 
a
l
.
 
2
0
0
0
)
K
i
-
6
7
 
1
0
q
2
5
 
I
H
C
 
P
r
o
g
r
e
s
s
i
o
n
/
r
e
c
u
r
r
e
n
c
e
 
(
G
e
r
d
e
s
 
e
t
 
a
l
.
 
1
9
8
4
)
c
y
c
l
i
n
 
D
1
 
1
1
q
1
3
 
I
H
C
 
L
o
w
 
g
r
a
d
e
/
l
o
w
 
s
t
a
g
e
/
r
e
c
u
r
r
e
n
c
e
 
(
W
a
g
n
e
r
 
e
t
 
a
l
.
 
1
9
9
9
;
 
L
i
u
k
k
o
n
e
n
 
e
t
 
a
l
.
 
2
0
0
0
)
c
y
c
l
i
n
 
E
 
1
9
q
1
2
 
I
H
C
 
L
o
w
 
s
t
a
g
e
/
s
u
r
v
i
v
a
l
 
(
R
i
c
h
t
e
r
 
e
t
 
a
l
.
 
2
0
0
0
;
 
K
a
m
a
i
 
e
t
 
a
l
.
 
2
0
0
1
)
C
e
l
l
 
A
d
h
e
s
i
o
n
 
M
o
l
e
c
u
l
e
s
 
 
 
 
M
M
P
-
2
 
1
6
q
1
3
 
P
C
R
 
H
i
g
h
 
s
t
a
g
e
/
s
u
r
v
i
v
a
l
 
(
K
a
n
a
y
a
m
a
 
e
t
 
a
l
.
 
1
9
9
8
)
E
-
c
a
d
h
e
r
i
n
 
1
6
q
2
2
.
1
 
I
H
C
 
H
i
g
h
 
g
r
a
d
e
/
h
i
g
h
 
s
t
a
g
e
/
 
(
B
r
i
n
g
u
i
e
r
 
e
t
 
a
l
.
 
1
9
9
3
;
 
O
t
t
o
 
e
t
 
a
l
.
 
1
9
9
4
;
 
 
 
 
 
p
r
o
g
r
e
s
s
i
o
n
/
s
u
r
v
i
v
a
l
 
L
i
p
p
o
n
e
n
 
a
n
d
 
E
s
k
e
l
i
n
e
n
,
 
1
9
9
5
;
 
 
 
 
 
R
o
s
s
 
e
t
 
a
l
.
 
1
9
9
5
;
 
S
y
r
i
g
o
s
 
e
t
 
a
l
.
 
1
9
9
8
)
 
 
 
 
B
y
r
n
e
 
e
t
 
a
l
.
 
2
0
0
1
)
C
D
4
4
 
1
1
p
1
3
 
P
C
R
 
H
i
g
h
 
s
t
a
g
e
/
s
u
r
v
i
v
a
l
 
(
M
a
t
s
u
m
u
r
a
 
e
t
 
a
l
.
 
1
9
9
5
;
 
M
i
y
a
k
e
 
e
t
 
a
l
.
 
2
0
0
2
)
I
H
C
:
 
I
m
m
u
n
o
h
i
s
t
o
c
h
e
m
i
s
t
r
y
P
C
R
:
 
p
o
l
y
m
e
r
a
s
e
 
c
h
a
i
n
 
r
e
a
c
t
i
o
nBiomarker Insights 2007: 2 98
Wun-Jae Kim et al
response markers, although some studies have 
come to contradictory conclusions (Schmitz-
Drager et al. 2000; Sarkis et al. 1995; Sengelov 
et al. 1997). Another interesting tumor suppressor 
gene is Rb. Cordon-Cardo et al. (1992) have 
reported that patients with Rb-normal bladder 
tumors have a higher overall survival, independent 
of stage, than patients with Rb-altered tumors. 
Logothetis et al. (1992) also reported that of their 
group of patients with locally advanced bladder 
cancer that had been treated by surgery and chemo-
therapy, the patients whose tumors expressed an 
altered Rb protein had signiﬁ  cantly poorer tumor-
free survival rates. These observations were 
supported by Cote et al. (1998), who examined the 
IHC expression of the p53 and Rb proteins from 
the bladder cancers of 185 patients who had under-
gone radical cystectomy. This study found that 
patients whose tumors had altered expression 
levels of both p53 and Rb had significantly 
increased recurrence rates and decreased survival 
compared with those showing normal expression 
levels. Patients with altered expression levels of 
only one of these proteins had intermediate rates 
of recurrence and survival. Although this was a 
retrospective study that examined only a relatively 
small number of subjects, the results nevertheless 
indicate that dual analysis of Rb and p53 protein 
may improve the prognostic signiﬁ  cance of p53 
expression.
Cell cycle regulators
Among the patients whose bladder cancers showed 
altered p53 expression levels, some patients also 
exhibited negative p21 expression. Those patients 
that were p21 negative and abnormal for p53 
expression had a signiﬁ  cantly higher recurrence 
rate and worse survival compared with those whose 
tumors were p21-positive (Stein et al. 1998). 
However, the prognostic value of p21 expression 
remains to be validated. Another interesting cell 
cycle regulator is p27. A multivariate analysis of 
patients with invasive tumors has revealed that 
decreased p27 expression is associated with poor 
overall and post-relapse survival (Korkolopoulou 
et al. 2000). Moreover, this study found that low 
p27 expression in combination with high Ki-67 
expression was particularly strongly associated 
with poor overall survival (Korkolopoulou et al. 
2000). Numerous multivariate analyses have found 
that Ki-67 by itself is also an independent prog-
nostic marker of superﬁ  cial bladder cancer progres-
sion and recurrence. In normal situations, IHC-
detected Ki-67 antigen accumulates in the nuclei 
of proliferating cells from the G1 phase to mitosis 
but is absent from the nuclei of quiescent or resting 
cells (Gerdes et al. 1984). The studies examining 
the prognostic signiﬁ  cance of Ki-67 expression 
have all yielded similar observations, which 
suggests this promising marker should be tested in 
larger prospective studies with standardized posi-
tive criteria (especially with regard to the cutoff 
value of the labeling index). However, the prog-
nostic value of Ki-67 for patients with locally 
advanced or metastatic bladder cancer remains 
unclear.
With regard to the cyclins, changed expression 
levels of cyclin D1 have been shown to serve as 
an independent predictor of tumor recurrence, 
although they are not associated with disease 
progression (Wagner et al. 1999; Liukkonen et al. 
2000). A study of a tissue microarray composed of 
2,317 bladder cancer specimens (Ta to T3) revealed 
that while low cyclin E expression was generally 
associated with poor overall survival, it had virtu-
ally no prognostic value when analyzed indepen-
dently of the tumor stage (Richter et al. 2000). 
However, Kamai et al. (2001) have reported that 
low cyclin E expression in a cohort of 145 consec-
utive bladder cancer patients was an independent 
predictor of overall survival. Thus, the prognostic 
value of cyclin E expression remains to be 
conﬁ  rmed with further investigations.
Cell adhesion molecules
High levels of matrix metalloproteinase–2 (MMP-2), 
tissue inhibitors of matrix metalloproteinase–2 
(TIMP-2), and membrane-type MMP-1 expression 
have been strongly associated with decreased 
survival (Kanayama et al. 1998). However, it 
remains unknown whether the balance between the 
activity of MMPs and that of their inhibitors in 
serum or tissues can predict progression in patients 
with bladder cancer.
Reduced E-cadherin expression appears to be 
generally associated with increased muscle inva-
sion and distant metastasis as well as with higher 
pathologic grades and stages (Bringuier et al. 1993; 
Otto et al. 1994). High E-cadherin expression has 
also been associated with improved overall 
survival and recurrence-free survival (Bringuier 
et al. 1993; Lipponen and Eskelinen, 1995; Biomarker Insights 2007: 2 99
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Ross et al. 1995; Syrigos et al. 1998). Moreover, 
Byrne et al. (2001) have reported that altered IHC-
detected E-cadherin expression is signiﬁ  cantly 
associated with disease progression and cancer-
speciﬁ  c survival, and that E-cadherin and stage are 
independent predictors of disease progression. 
Thus, E-cadherin expression may be a promising 
prognostic variable. Another potential prognostic 
marker may be CD44, which is a widely expressed 
cell surface adhesion molecule that is involved in 
cell-cell and cell-matrix interactions. Two studies 
have shown that CD44 overexpression is closely 
associated with bladder cancer progression 
(Matsumura et al. 1995; Miyake et al. 2002).
In summary, the observations described above 
reveal a number of signiﬁ  cant correlations between 
various molecular markers and tumor progression. 
In particular, p53, Ki-67, Rb, EGFR, E-cadherin 
and several cyclins appear to be of prognostic value 
with regard to bladder cancer metastasis, recur-
rence, and overall and cancer-speciﬁ  c survival. 
However, none of these markers are currently being 
utilized in clinical practice and their usefulness as 
independent prognosticators remains to be 
confirmed by large prospective comparative 
studies. More reliable and accurate methods to 
detect these markers should also be developed to 
improve their utility in the clinic.
Epigenetic Markers
While genetics refers to the study of information 
inherited on the basis of gene sequence, epigenetics 
is the study of reversible changes that can be inher-
ited in gene function or other cell phenotypes that 
occur without any change in DNA sequence. One 
example of such epigenetic changes is DNA meth-
ylation, which can induce different gene expression 
patterns in a tissue-speciﬁ  c and developmental-
stage-speciﬁ  c manner. DNA methylation occurs 
throughout the genome and involves the addition 
of a methyl group to the cytosine ring of the CpG 
dinucleotide. The methylation process is catalyzed 
by an enzyme called DNA methyltransferases and 
it results in formation of methyl cytosines. DNA 
methylation within a promoter region is associated 
with silencing of the afﬁ  liated gene. The methyla-
tion pattern is established during development and 
is normally maintained throughout the life of an 
individual. Thus, DNA methylation is a key regu-
lator of gene transcription and genomic stability 
and inappropriately altered DNA methylation 
pattern is a frequently detected epigenetic change 
in human cancers (Table 2). 
In carcinogenesis, the mechanisms that gener-
ally regulate normal DNA methylation pattern are 
impaired and many cancers consequently show 
global hypomethylation accompanied by regional 
hypermethylation found in some promoter 
sequences. Thus, the detection of aberrant DNA 
promoter hypermethylation in cancers may be of 
considerable prognostic value (Dulaimi et al. 
2004), particularly when the aberrant hypermeth-
ylation silences tumor suppressor genes (Herman 
and Baylin, 2003). For example, hypermethylation 
of the Rb tumor suppressor gene has been strongly 
connected with tumorigenesis because only about 
9% of retinoblastomas nomally exhibit hypermeth-
ylation of their 5' regions (Ohtani-Fujita et al. 
1997). Since the promoters of many tumor 
suppressor genes contain CpG islands and show 
evidence of methylation-specific silencing, 
abnormal methylation of CpG islands may act as 
a key tumorigenic ‘‘hit’’ (Baylin and Herman, 
2000; Jones and Laird 1999). Consequently, 
analyses of altered DNA methylation in cancers 
often focus on the CpG islands in the promoters of 
tumor suppressor genes. 
As promoter hypermethylation occurs frequently 
in bladder cancer (Catto et al. 2005), several 
authors have investigated its presence in exfoliated 
urinary cells or tumor tissues (Kim et al. 2005; 
Maruyama et al. 2001; Chan et al. 2002; Dulaimi 
et al. 2004; Friedrich et al. 2004; Yates et al. 2006). 
Kim et al. (2005) demonstrated that methylation 
of RUNX3 promoter sequence confers a 100-fold 
increased risk of developing bladder cancer (OR, 
107.55). RUNX3 methylation also appears to be 
positively associated with cancer stage (OR, 2.95), 
recurrence (OR, 3.70), and progression (OR, 5.63), 
which suggests that RUNX3 not only inhibits 
cancer initiation but also suppresses the aggres-
siveness of primary bladder cancers. Thus, the 
methylation status of RUNX3 may be a better 
diagnostic marker for bladder cancer than previ-
ously described markers. 
Catto et al. (2005) have analyzed the hyper-
methylation at 11 CpG islands in a large cohort of 
urothelial carcinomas. Compared with unmethyl-
ated tumors, methylation at these sites was signif-
icantly associated with advanced stage, high tumor 
progression rates, and increased mortality rates. 
These ﬁ  ndings strongly suggest that patterns of 
promoter hypermethylation may actually be a Biomarker Insights 2007: 2 100
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cause of bladder cancer, at least in part. Thus, 
analysis of the methylation status may be useful 
as a diagnostic and prognostic marker for bladder 
cancer. Moreover, reversing aberrant methylation 
may be an effective way to treat bladder cancer. 
Dulaimi et al. (2004) compared the matched 
sediment DNAs from urine specimens obtained 
before surgery with normal and benign control 
DNAs for the methylation status of three tumor 
suppressor genes, namely, APC, RASSF1A, and 
p14
ARF. Hypermethylation of at least one of these 
genes was found in the matched urine DNA from 
39 of 45 patients (87% sensitivity; 100% speci-
ficity), including 16 cases that had negative 
cytology. Indeed, hypermethylation (91%) in the 
urine DNA was more commonly detected than 
positive cytology (50%). Similarly, another group 
has also investigated the DNA methylation status 
of various apoptosis-associated genes (DAPK, 
BCL2, TERT, EDNRB, RASSF1A, and TNFRSF25) 
in urine sediments (Friedrich et al. 2004) and found 
that hypermethylation of the DAPK, BCL2, and 
TERT genes was highly sensitive (78%) and 
speciﬁ  c (100%) in detecting bladder cancer. Thus, 
the detection of DNA hypermethylation in voided 
urine is promising in terms of the early detection 
and surveillance of bladder cancer. 
There are, however, a number of criticisms of 
the clinical and prognostic relevance of assays 
detecting promoter hypermethylation in bladder 
cancer. Firstly, some markers, such as RASSF1, 
can be commonly observed in primary tumors 
including lung, breast, pancreas, kidney, liver, 
cervix, nasopharyngeal, prostate, thyroid and other 
cancers. Moreover, RASSF1A methylation was 
frequently detected in body ﬂ  uids including blood, 
urine, nipple aspirates, sputum and bronchial 
alveolar lavages. Inactivation of RASSF1A was 
associated with an advanced tumor stage (e.g. 
bladder, brain, prostate, gastric tumors) and poor 
prognosis (e.g. lung, sarcoma and breast cancer). 
Detection of aberrant RASSF1A methylation may 
serve as a diagnostic and prognostic marker 
(Damman et al. 2005; Maruyama et al. 2005). Even 
though a speciﬁ  c methylation marker in bladder 
cancer might be promising in terms of its prog-
nostic value, the most powerful detection tools 
established up to date, such as cystoscopy in 
bladder cancer and PSA in prostate cancer should 
be ﬁ  rstly considered and methylation markers must 
be used to support the function of primary detection 
methods. In the near future, it may be possible that 
technologies will become available to characterize 
different methylation patterns related to various 
cancer types. Secondly, several studies of promoter 
methylation produced largely contradictory results, 
which weakened the argument for the inspection 
of promoter methylation patterns as a prognostic 
method. Eventually, new methodologies might 
explain these discrepancies, but these dissimilari-
ties emphasize the need for standardized method-
ological protocols if molecular diagnostic tools are 
to be a useful component of routine clinical prac-
tice. Additionally, discrepancies between methyla-
tion profiles and gene expression have been 
reported, thus raising the issue of whether DNA 
methylation is the cause of gene down regulation. 
Earlier, we reported strong evidence suggesting 
that RUNX3 is a bladder cancer tumor suppressor 
gene and that it is frequently inactivated by hyper-
methylation of the promoter region (Kim et al. 
2005). Therefore, promoter hypermethylation, 
including that of RUNX3, could induce not only 
gene down regulation, but also tumorigenesis. 
Gene Expression Proﬁ  les as 
Promising Bladder Cancer Markers
New high-throughput microarray technologies 
have made it possible to gain a comprehensive 
insight into the molecular basis of many human 
diseases (Bubendorf, 2001). In particular, 
searching for the genes that are differentially 
expressed in human cancers has been greatly 
facilitated by DNA microarray technology. With 
this technology, the RNA expression levels of 
hundreds or even thousands of genes in a tumor 
can be surveyed simultaneously. The tissue micro-
array technology has also been developed to enable 
a large-scale molecular analysis of hundreds of 
tumor samples. Oligonucleotide arrays, such as 
those manufactured by Affymetrix (www.affyme-
trix.com) or Illumina (www.illumina.com), repre-
sent some standardized approaches that are being 
widely accepted. These microarrays consist of 
grids bearing thousands of 20–25 or 50 bp oligo-
nucleotides that have been selected from known 
sequences by design algorithms that choose probes 
that hybridize to their complements with high 
afﬁ  nity and speciﬁ  city (Lipshutz et al. 1999; Lock-
hart et al. 1996). Each ﬂ  uorescently labeled sample 
of mixed nucleic acids is hybridized to the array 
individually. This results in the quantitation of 
absolute gene expression levels. In contrast, cDNA Biomarker Insights 2007: 2 102
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microarrays require ﬂ  uorescent labeling of nucleic 
acids isolated from a test sample (e.g. bladder 
cancer tissue) and differently labeled nucleic acids 
from a reference sample (e.g. normal bladder 
tissue) (Duggan et al. 1999; Schena et al. 1995). 
The results thus generate ratios of gene expression 
of the test sample relative to that of the reference 
sample. cDNA arrays are commercially available 
or may be fabricated speciﬁ  cally to assay the 
experimental system in question (Cheung et al. 
1999).
Recently, Illumina has generated two kinds of 
BeadChips to analyze human gene expression. The 
HumanRef-8 Expression BeadChip, which 
has >24,000 probes, generates the whole-genome 
expression proﬁ  les of eight samples on a single 
BeadChip. The HumanRef-8 BeadChip array 
represents genome-wide transcriptional coverage 
of well-characterized National Center for Biotech-
nology Information (NCBI) Reference Sequence 
(RefSeq; Release 4) genes. These RefSeq genes 
are validated, annotated, and curated on an ongoing 
basis by NCBI staff and collaborators. The Human-
6 BeadChip generates the whole-genome expres-
sion proﬁ  les of six samples on a single BeadChip. 
Each Human-6 BeadChip microarray contains 
>47,000 probes and targets >46,000 human tran-
scripts and represents genome-wide transcriptional 
coverage of well-characterized genes, gene candi-
dates, and splice variants. The per-sample probe 
content is designed and assembled hierarchically. 
One stripe in each array pair is based on the same 
RefSeq genes found in the HumanRef-8 BeadChip, 
while the second stripe includes probes for genes 
with unique locations in the human genome, such 
as expressed sequence tags (ESTs) or those that 
appear in multiple independent databases. The 
probes are speciﬁ  cally designed to avoid querying 
pseudogenes and SNP sites. These microarray 
technologies are and will be of considerable value 
in the urological ﬁ  eld. In particular, microarray 
gene expression analysis is likely to greatly facil-
itate the identiﬁ  cation of molecular prognostic 
markers that correlate with particular bladder 
cancer outcomes. 
Bladder cancer frequently occurs as multifocal 
disease involving several simultaneous tumors 
scattered over the bladder. Modlich et al. (2004) 
have reported that multifocal superﬁ  cial bladder 
cancers always cluster together, which suggests 
they share a common genetic background. The 
clonality of multifocal bladder cancer has also been 
reported by several other studies, which are based 
on comprehensive LOH analyses (Hartmann et al. 
2000; Sidransky et al. 1992). Tissue RNA expres-
sion microarrays of the multifocal tumors would 
be useful in conﬁ  rming the genetic homogeneity 
of multifocal tumor cells.
Bladder cancers also present as invasive 
cancers, which are histologically complex tissues 
that consist of a variety of cell types other than 
carcinoma cells. As with other methods, tissue 
RNA expression microarrays determine the expres-
sion levels irrespective of cell types. Despite this, 
tissue RNA expression microarray analyses of 
invasive bladder cancers may also offer some 
important clinical information. This is due to the 
fact that tumor development and progression (e.g. 
growth, angiogenesis, tumor cell detachment, and 
invasion) are dependent on interactions between 
tumor cells and the host microenvironment 
(stroma). Hence, the expression of factors involved 
in tumor-cell stroma interactions may reflect 
important biological properties that are indepen-
dent of cellular origin (Primdahl et al. 2002; Keleg 
et al. 2003; Hsu et al. 2002; Liotta and Kohn, 2001; 
Seripa et al. 2001). Indeed, while microdissection 
would allow the examination of highly pure tumor 
cell populations of a given specimen, it might not 
reﬂ  ect the tumor itself in vivo. Thus, identiﬁ  cation 
of a molecular classiﬁ  er gene set, which is to 
certain extent independent of tumor tissue hetero-
geneity, is required. 
With regard to the microarray studies that have 
been performed in the bladder cancer ﬁ  eld to date, 
Sanchez-Carbayo et al. (2003) have used cDNA 
microarrays to facilitate the hierarchical clustering 
of superﬁ  cial and invasive bladder cancers. This 
technology allowed them to separate carcinoma in 
situ from papillary superﬁ  cial lesions, and to iden-
tify subgroups within superﬁ  cial and invasive 
cancers that differ in overall survival. The most 
extensive expression proﬁ  ling study of bladder 
cancers reported to date is by Dyrskjot and 
coworkers (Dyrskjot, 2003; Dyrskjot et al. 2003), 
who identiﬁ  ed clinically relevant subclasses of 
bladder cancer on the basis of their expression 
microarray proﬁ  les. Cluster analysis identiﬁ  ed 
three major stages, namely, Ta, T1 and T2-4, with 
the Ta tumors being further classified into 
subgroups. In particular, a 32-gene molecular clas-
siﬁ  er set of genes could be used to classify benign 
and muscle invasive cancers with a close correla-
tion to pathological staging. This analysis also Biomarker Insights 2007: 2 103
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provided new predictive information on disease 
progression in Ta tumors as compared with conven-
tional staging. Furthermore, the gene expression 
proﬁ  les that characterized each stage and subtype 
revealed their biological properties, thereby iden-
tifying new potential targets for therapy. Dyrskjot 
et al. (2004) then extended their work by examining 
the gene expression patterns of muscle invasive 
carcinomas and superﬁ  cial transitional cell carci-
nomas with and without surrounding carcinoma in 
situ. The transitional cell carcinomas with 
surrounding carcinoma in situ and invasive carci-
nomas showed similar expression levels of a few 
gene clusters. As a result, a 16-gene molecular 
classiﬁ  er that represents the bladder carcinoma in 
situ gene expression signature was constructed. 
This classiﬁ  er was suggested to be useful in the 
follow-up of bladder cancer patients. 
Modlich et al. (2004) subjected tumor speci-
mens of a cohort of uniformly treated patients with 
a well-deﬁ  ned clinical outcome to hierarchical 
cluster analysis. Superﬁ  cial and invasive tumors 
were found to display distinct gene expression 
proﬁ  les. Moreover, distinct prognostic groups of 
invasive bladder cancer could be identiﬁ  ed. When 
different subsets of gene expression data, including 
a set of 41 genes, were analyzed by using two 
different array platforms, the gene and tumor clus-
tering patterns were remarkably stable. Superﬁ  cial 
tumors were also found to be of clonal origin, and 
different areas of invasive tumors showed highly 
similar gene expression patterns. Moreover, the 
bladder mucosa of patients with locally advanced 
disease was shown to express an invasive type of 
pattern. These data thus provide additional insights 
into the molecular pathogenesis of bladder cancer 
and help detect novel prognostic markers for super-
ﬁ  cial, invasive, and metastasizing disease.
Blaveri et al. (2005) have characterized the 
global gene expression patterns in 80 bladder 
cancers, 9 bladder cancer cell lines, and 3 normal 
bladder samples by cDNA microarrays containing 
10,368 human gene elements. Unsupervised hier-
archical clustering successfully separated the 
samples into two subgroups that contained super-
ﬁ  cial (pTa and pT1) or muscle invasive (pT2–pT4) 
tumors. Supervised classification based on a 
limited subset of genes had a 90.5% success rate 
in separating superﬁ  cial from muscle invasive 
tumors. Tumors could also be classiﬁ  ed into tran-
sitional versus squamous subtypes (89% success 
rate) and a good versus bad prognosis (78% success 
rate). It was concluded that the genes driving the 
separation between tumor subsets may be impor-
tant biomarkers for bladder cancer development 
and progression. Furthermore, these biomarkers 
could be candidates for therapeutic targeting.
The full utility of microarray analyses in bladder 
cancer research, diagnosis, prognosis, and treatment 
remains to be determined by additional clinical trials. 
One particularly critical issue that should be 
addressed by microarray analyses is the identiﬁ  cation 
of superﬁ  cial disease subtypes and the patients who 
are more likely to develop positive lymph nodes or 
distant metastases. It is likely that in the near future, 
gene proﬁ  ling will be an effective way of predicting 
the response to speciﬁ  c therapeutic regimes, as it will 
determine the molecular signatures of the tumors 
with respect to their chemosensitivity or resistance 
to anticancer drugs. Moreover, the discovery of 
prognostic markers in cancer progression, as well as 
the identiﬁ  cation of molecule-susceptible targets, 
will lead to the development of novel alternative 
therapies. Thus, the classical concept of the tumor 
marker is currently being expanded from an indi-
vidual biological determinant to gene clusters that 
can act as predictive classiﬁ  ers.
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